Delving into the Latest Updates on bioeq GmbH with Synapse

A Randomised, Double-blind, Parallel-group, Phase 3 Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.

开始日期2020-11-09

申办/合作机构

bioeq GmbH

JPRN-jRCT2080225278 / Completed临床3期

A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea in Patients with Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

开始日期2020-08-03

申办/合作机构

bioeq GmbH

NCT04522167 / Completed临床3期

A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.

开始日期2020-07-21

申办/合作机构

bioeq GmbH

100 项与 bioeq GmbH 相关的临床结果

登录后查看更多信息

0 项与 bioeq GmbH 相关的专利（医药）

登录后查看更多信息

2

项与 bioeq GmbH 相关的文献（医药）

2022-01-01·Ophthalmology1区 · 医学

Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

1区 · 医学

Article

作者: Schmitz-Valckenberg, Steffen ; Kiefer, Joachim ; Oleksy, Piotr ; Ricci, Federico ; Holz, Frank G ; Kaiser, Peter K

PURPOSEThis trial was conducted to investigate the clinical equivalence of the proposed biosimilar FYB201 and reference ranibizumab in patients with treatment-naive, subfoveal choroidal neovascularization caused by neovascular age-related macular degeneration (nAMD).DESIGNThis was a prospective, multicenter, evaluation-masked, parallel-group, 48-week, phase III randomized study.PARTICIPANTSA total of 477 patients were randomly assigned to receive FYB201 (n = 238) or reference ranibizumab (n = 239).METHODSPatients received FYB201 or reference ranibizumab 0.5 mg by intravitreal (IVT) injection in the study eye every 4 weeks.MAIN OUTCOME MEASURESThe primary end point was change from baseline in best-corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at 8 weeks before the third monthly IVT injection. Biosimilarity of FYB201 to its originator was assessed via a 2-sided equivalence test, with an equivalence margin in BCVA of 3 ETDRS letters.RESULTSThe BCVA improved in both groups, with a mean improvement of +5.1 (FYB201) and +5.6 (reference ranibizumab) ETDRS letters at week 8. The analysis of covariance (ANCOVA) least squares mean difference for the change from baseline between FYB201 and reference ranibizumab was -0.4 ETDRS letters with a 90% confidence interval (CI) of -1.6 to 0.9. Primary end point was met as the 90% CI was within the predefined equivalence margin. Adverse events were comparable between treatment groups.CONCLUSIONSFYB201 is biosimilar to reference ranibizumab in terms of clinical efficacy and ocular and systemic safety in the treatment of patients with nAMD.

2020-06-01·BioDrugs3区 · 医学

The Path Towards a Tailored Clinical Biosimilar Development

3区 · 医学

Review

作者: Maréchal-Jamil, Julie ; Ranganna, Gopinath ; Jung, Byoungin ; Roth, Karsten ; Schiestl, Martin ; Watson, Keith ; Trieb, Michael ; Capsius, Björn ; Bias, Peter

Since the first approval of a biosimilar medicinal product in 2006, scientific understanding of the features and development of biosimilar medicines has accumulated. This review scrutinizes public information on development programs and the contribution of the clinical studies for biosimilar approval in the European Union (EU) and/or the United States (US) until November 2019. The retrospective evaluation of the programs that eventually obtained marketing authorization and/or licensure revealed that in 95% (36 out of 38) of all programs, the comparative clinical efficacy studies confirmed similarity. In the remaining 5% (2 out of 38), despite meeting efficacy outcomes, the biosimilar candidates exhibited clinical differences in immunogenicity that required changes to the manufacturing process and additional clinical studies to enable biosimilar approval. Both instances of clinical differences in immunogenicity occurred prior to 2010, and the recurrence of these cases is unlikely today due to state-of-the-art assays and improved control of process-related impurities. Biosimilar candidates that were neither approved in the EU nor in the US were not approved due to reasons other than clinical confirmation of efficacy. This review of the development history of biosimilars allows the proposal of a more efficient and expedited biosimilar development without the routine need for comparative clinical efficacy and/or pharmacodynamic studies and without any compromise in quality, safety, or efficacy. This proposal is scientifically valid, consistent with regulation of all biologics, and maintains robust regulatory standards in the assessment of biosimilar candidates. Note: The findings and conclusion of this paper are limited to biosimilar products developed against the regulatory standards in the EU and the US.

100 项与 bioeq GmbH 相关的药物交易

登录后查看更多信息

100 项与 bioeq GmbH 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床3期

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿柏西普生物类似药 (Formycon) ( PGF x VEGF-A )	湿性年龄相关性黄斑变性更多	临床3期
雷珠单抗生物类似药(Formycon AG) ( VEGF-A )	湿性年龄相关性黄斑变性更多	无进展